Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Invested Capital (2019 - 2025)

Bioadaptives' Invested Capital history spans 7 years, with the latest figure at -$497804.0 for Q3 2025.

  • For Q3 2025, Invested Capital rose 35.92% year-over-year to -$497804.0; the TTM value through Sep 2025 reached -$497804.0, up 35.92%, while the annual FY2024 figure was -$410669.0, 38.59% up from the prior year.
  • Invested Capital for Q3 2025 was -$497804.0 at Bioadaptives, down from -$370662.0 in the prior quarter.
  • Across five years, Invested Capital topped out at -$370662.0 in Q2 2025 and bottomed at -$804763.0 in Q3 2022.
  • The 5-year median for Invested Capital is -$665286.0 (2022), against an average of -$610007.7.
  • The largest annual shift saw Invested Capital soared 64.37% in 2021 before it plummeted 77.66% in 2024.
  • A 5-year view of Invested Capital shows it stood at -$535997.0 in 2021, then crashed by 42.66% to -$764645.0 in 2022, then rose by 12.54% to -$668759.0 in 2023, then skyrocketed by 38.59% to -$410669.0 in 2024, then decreased by 21.22% to -$497804.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Invested Capital are -$497804.0 (Q3 2025), -$370662.0 (Q2 2025), and -$579464.0 (Q1 2025).